Driehaus Capital Management
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies.
Business Model:
Revenue: $4.7M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Driehaus Capital Management Information
Geographic Data
Address: 25 East Erie Street
City: Chicago
State: IL
Zip: 60611
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$82M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
3,640,526Website Global Rank
3,627Website Monthly Traffic
Twitter Followers
Description
Driehaus is an investment management firm that manages growth equity investment strategies and multi-asset alternative strategies. The firm has a diverse institutional client base comprised of corporate and public pensions, endowments, foundations, sub-advisory, family offices, wealth managers, and financial advisors, globally. Driehaus is a performance-oriented investment management boutique that emphasizes integrity, transparency, and the alignment of the firm’s interests with its clients. The firm was founded in 1982 and is headquartered in Chicago, Illinois.
Contact Phone:
+13125873800
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 7/2019 | Frontier Medicines | Series B | 88.5M |
| 4/2021 | C2i Genomics | Series B | 0 |
| 2/2021 | Vividion Therapeutics | Series C | 135M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 9/2022 | Ventyx Biosciences | Post-IPO Equity | 0 |
| 7/2020 | Thrive Earlier Detection | Series B | 0 |
| 7/2020 | Frequency Therapeutics | Post-IPO Equity | 42.3M |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 75M |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 1/2021 | DarioHealth | Post-IPO Equity | 70M |
| 2/2019 | Peloton Therapeutics | Series E | 0 |
| 8/2016 | Trace.com | Seed Round | 895k |
| 5/2019 | Pulmonx | Series G | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 10/2022 | VectivBio | Post-IPO Equity | 0 |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2018 | IDEAYA Biosciences | Series B | 0 |
| 6/2000 | Alloptic | Venture Round | 8M |
| 9/2022 | Sonendo | Post-IPO Equity | 63M |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 7/2020 | Elevation Oncology | Series A | 32.5M |
| 12/2019 | ArcherDX | Series C | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 7/2022 | Annexon Biosciences | Post-IPO Equity | 0 |
| 2/2022 | Congruence Therapeutics | Series A | 0 |
| 1/2022 | Maze Therapeutics | Venture Round | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
| 7/2021 | Frontier Medicines | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 5/2021 | NeoGenomics | Post-IPO Equity | 0 |
| 4/2021 | C2i Genomics | Series B | 0 |
| 4/2021 | Crinetics Pharmaceuticals | Post-IPO Equity | 0 |
| 3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
